EMA Withdrawn: Inflectra (infliximab) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA has withdrawn Inflectra (infliximab) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis
• Colitis Ulcerative
• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylitis Ankylosing

Drugs mentioned

• INFLECTRA (infliximab-dyyb)

Snippet

Status: Withdrawn. Therapeutic area: Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid. MAH: Pfizer Europe MA EEIG. Decision date: 16/02/2026